BioVaxys Technology Corp. (CSE: BIOV) announced preliminary results from its PESCO study, a phase 1B/2 trial evaluating MVP-S combined with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE